T1	Outcomes 1337 1371	levels of intraprostatic androgens
T2	Outcomes 1418 1471	primary end point (dihydrotestosterone/testosterone),
T3	Outcomes 1706 1737	incidence of complete responses
T4	Outcomes 1750 1767	residual disease,
T5	Outcomes 1880 1896	tissue androgens